Go to Page # Page of 32
loading

Drug Candidates Targeting the DNA Damage Response (DDR)

 Sierra Oncology, Inc.
  19th-Apr-2019
Description: Sierra is advancing two drug candidates targeting the DNA Damage Response. Cdc7 is a next-generation DDR target for cancer, with a key role in controlling the initiation of DNA replication.
Views: 2355
Domain: Medical
Category: Biotech/Pharma
Contributing Organization: Sierra Oncology, Inc.
 ‐ More of their Presentations
Contents:
Charting the path from
pioneering biology to
impactful therapeutics
AACR 2019 Late-Breaking Data for
SRA141 targeting Cdc7

NASDAQ: SRRA

S A F E H A R B O R S TAT E M E N T
Except for statements of historical fact, any information contained in this presentation may be a forward-looking
statement that reflects the Company’s current views about future events and are subject to risks, uncerta ... See more

Recent Presentations

PFCD
15 September, 2019
ISMP Canada
13 September, 2019
...
12 September, 2019